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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Abstract: The phenomenon of ischemic preconditioning has been recognized as one of the 
most potent mechanisms to protect against myocardial ischemic injury. In experimental ani-
mals and humans, a brief period of ischemia has been shown to protect the heart from more 
prolonged episodes of ischemia, reducing infarct size, attenuating the incidence, and severity 
of reperfusion-induced arrhythmias, and preventing endothelial cell dysfunction. Although the 
exact mechanism of ischemic preconditioning remains obscure, several reports indicate that this 
phenomenon may be a form of receptor-mediated cardiac protection and that the underlying 
intracellular signal transduction pathways involve activation of a number of protein kinases, 
including protein kinase C, and mitochondrial KATP channels. Apoptosis, a genetically pro-
grammed form of cell death, has been associated with cardiomyocyte cell loss in a variety of 
cardiac pathologies, including cardiac failure and those related to ischemia/reperfusion injury. 
While ischemic preconditioning signiﬁ  cantly reduces DNA fragmentation and apoptotic myocyte 
death associated with ischemia-reperfusion, the potential mechanisms underlying this effect have 
not been fully clariﬁ  ed. A comprehensive understanding of these mechanisms and application 
to clinical scenarios will provide new directions in research and translate this information into 
new treatment approaches for reducing the extent of ischemia/reperfusion injury.
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Preconditioning in experimental studies
In 1986, a group of investigators studying the intracellular changes of glycolytic prod-
ucts at different time points of myocardial ischemia in a canine model, observed that 
four cycles of 5 minutes ischemia and reperfusion prior to a more sustained episode 
of 40 min ischemia reduced considerably myocardial infarction compared with the 
control (Murry et al 1986). This was the ﬁ  rst description of an endogenous protective 
phenomenon called ischemic preconditioning. The same beneﬁ  cial effect was since 
then conﬁ  rmed in every species that was studied, independently of the presence of 
collaterals in the coronary circulation and independently of the size of the animal 
model (Schott et al 1990; Liu et al 1991; Liu and Downey 1992). Early studies mostly 
focused on the investigation of the natural history of preconditioning in terms of the 
number of brief ischemic episodes, the duration of each ischemic insult, the duration of 
the reperfusion interval that would separate the last cycle of preconditioning from the 
following sustained episode of ischemia and ﬁ  nally the duration of the prolonged isch-
emia in order the preconditioning to be effective (van Winkle et al 1991; Iliodromitis 
et al 1996). Species differences were observed regarding the number of brief episodes 
of ischemia: increased number of ischemic bursts was effective in protecting the dog 
heart (Li et al 1990) whereas protection was lost after a certain number of ischemic-
reperfusion stimuli in the rabbit heart (Cohen et al 1994; Iliodromitis et al 1997).
The preconditioned state is very transient following a preconditioning protocol 
and lasts for only 1–2 h in anesthetized animals (van Winkle et al 1991; Jenkins et al Vascular Health and Risk Management 2006:2(4) 465–475
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prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
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1995; Iliodromitis et al 1996). This constitutes the classic 
preconditioning or ﬁ  rst window of myocardial protection. 
Of note, later experimental studies revealed that, while the 
provided protection is lost after this reperfusion interval 
and the heart remains unprotected for several hours, the 
protective effect re-appears after 24 hours and lasts up to 72 
hours (Yellon and Baxter 1995; Yang et al 1996). This is the 
delayed phase of preconditioning or the second window of 
protection, which starts with no additional intervention, it is 
more prolonged although less robust.
The golden standard of the effectiveness of precondition-
ing is the reduction of the infarct size (Figure 1). However, 
there is a series of other beneﬁ  ts obtained from precondition-
ing and among these are the reduction of lethal arrhythmias 
and the better recovery of post-ischemic left ventricular 
Figure 1 The effect of ischemic preconditioning on infarct size after ischemia/
reperfusion. Upper panel:infarct size expressed as percent of risk zone size in 
control and preconditioned (IPC) rabbit hearts (from Iliodromitis et al 2006); 
lower panel: the absolute infarct volume plotted against absolute risk zone volume 
from control (closed symbols) and preconditioned (open symbols) hearts (from 
Iliodromitis et al 2004).
function (Shiki and Hearse 1987; Przyklenk 2000; Yellon 
and Downey 2003).
After the initial studies that elucidated the natural history 
of preconditioning in terms of the proper ischemic stimuli 
and time intervals, later experimental studies investigated the 
mechanisms that are involved in the protection mediated by 
preconditioning. The ﬁ  rst breakthrough in this direction was 
the report by Downey and colleagues (Liu et al 1991) that the 
adenosine A1 receptor acts to trigger ischemic precondition-
ing’s protection in the rabbit heart, revealing that ischemic 
preconditioning is receptor mediated. It has now become 
established that the protection is receptor mediated, and a 
major objective in recent years has been the identiﬁ  cation of 
the triggers, mediators and end effectors in the myocyte that 
are activated during ischemic preconditioning.
Activation of speciﬁ  c receptors on the cardiomyocyte 
cell membrane such as adenosine A1 and A3, bradykinin B2, 
α1-adrenergic, δ-opioid, and others, initiate a series of signal 
transduction cascades that carry the signal for protection and 
those presumably terminate on one or more end-effectors (Liu 
et al 1991; Cohen et al 2001; Schulz et al 2001). In recent 
years, much research has focused on the key role of the mito-
chondrial KATP channel as both a trigger and distal effector 
in preconditioning with equivocal results (Pain et al 2000; 
Fryer et al 2000; Sato et al 2000; Iliodromitis et al 2003; 
O’Rourke 2004). The signal transduction pathways down-
stream of the trigger are complex and a detailed description 
is beyond the scope of this review. However, it is clear that 
multiple protein kinases are involved, notably one or more 
isoforms of protein kinase C, at least two tyrosine kinases 
(eg, Src and PI3 kinase), as well as mitogen-activated protein 
kinases (Baines et al 1998; Iliodromitis et al 1998; Harada 
et al 2004; Armstrong 2004; Hausenloy et al 2005). Reperfu-
sion injury salvage kinase (RISK) pathway has emerged as 
a concept and describes a group of survival protein kinases, 
which include Akt and Erk1/2 that confer powerful cardio-
protection against lethal reperfusion injury when speciﬁ  cally 
activated at the time of reperfusion (Hausenloy and Yellon 
2007). The cardioprotective effect of ischemic precondi-
tioning is completely aborted by inhibiting RISK pathway 
(Hausenloy et al 2005).
More recently another endogenous mechanism of protec-
tion, called postconditioning, was described. In brief, a series 
of very short-lived episodes of ischemia and reperfusion 
applied at the onset of reperfusion after an index ischemic 
event reduce the infarct size. Postconditioning is more easily 
applicable and does not require fore-knowledge of a poten-
tially lethal ischemic event. RISK pathway is also involved Vascular Health and Risk Management 2006:2(4) 465–475
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in the cardioprotective mechanism of postconditioning and 
the inhibition of PI3 kinase abrogates protection conferred 
by postconditioning (Tsang et al 2004). It has been suggested 
that the RISK pathway “unites” both ischemic precondition-
ing and postconditioning at the time of reperfusion (Haus-
enloy and Yellon 2007).
Preconditioning in humans
The acquired experience from the experimental studies 
was transferred to humans and the protective effect of 
preconditioning was examined using direct or indirect obser-
vations (Kloner et al 1995a, 1995b; Andreotti et al 1996; 
Kobayashi et al 1997; Karbanda et al 2001). It is difﬁ  cult to 
transfer the strict laboratory conditions regarding the number 
and the duration of episodes of ischemia and reperfusion, 
into the clinical reality, so much for practical reasons as 
well as for ethical reasons. Thus, the ﬁ  nal end points for the 
assessment of protection in humans are more or less indirect. 
Furthermore, the precise estimation of the infarct size and the 
area at risk is not very easy to be determined in humans and 
therefore the beneﬁ  cial effect of preconditioning is difﬁ  cult 
to be assessed. However, as in the experimental models, 
other surrogate end-points are used for the expression of the 
salutary effect of preconditioning and among these are the 
reduction of the episodes of angina after an initial episode, 
the reduction of ST deviation on the electrocardiogram, the 
reduction of lethal arrhythmias, a smaller peri-operative 
infarction, a better survival of the patients with pre-infarction 
angina and others (Tomai et al 1996, 1997; Ishihara et al 
1997; Gheeraert et al 2001).
The preconditioning studies can be divided into observa-
tional, provocative, and pharmacological. In the ﬁ  rst category 
belong those studies where the patients describe alleviation 
of their symptoms or there is an objective method which can 
conﬁ  rm the beneﬁ  t of preconditioning. In fact, many patients 
report an episode of angina early in the morning, called walk-
through or warm up angina and they remain free of symptoms 
later and for the rest of the day (Przyklenk and Kloner 1999; 
Schwarz et al 1999). There are a large number of clinical 
studies which have shown that pre-infarction angina acts as 
preconditioning stimulus and the patients develop smaller 
CK-determined myocardial infarction in comparison to the 
patients without pre-infarction angina. In the objective stud-
ies, it is feasible to describe the effect of an intervention that 
may act as a preconditioning analogue. In this regard, less 
ST segment shift, less extent of angina and less lactate pro-
duction at the second balloon inﬂ  ation compared to the ﬁ  rst 
are some surrogate end-points attributed to an effect called 
coronary angioplasty-related preconditioning (Tomai et al 
1996, 1997). Furthermore, there is evidence that the second 
exercise treadmill test becomes better in comparison to the 
ﬁ  rst and this may express an early or delayed precondition-
ing effect (Paraskevaidis et al 2005). Objective description 
of preconditioning has been also obtained from histological 
studies of tissue samples like atrial trabeculae or ventricular 
tissue taken at the time of operation or by the peripheral mark-
ers that have been used for the expression of preconditioning 
(Yellon et al 1993; Jenkins et al 1997).
Another interesting issue is the pharmacological stimula-
tion of preconditioning and the expectation that several agents 
involved in the mechanism of protection could become safe 
and easily applicable preconditioning mimetics. Adenosine, 
acadesine, ACE inhibitors which prevent bradykinin deg-
radation, nicorandil, and others have been used in clinical 
studies. In the AMISTAD study, adenosine has been used 
in parallel with thrombolysis in patients with evolving myo-
cardial infarction and resulted in reduction of the infarct size 
in anterior myocardial infarction despite the fact that it was 
administered after the onset of chest pain (Mahaffey et al 
1999). In the AMISTAD II study, the adenosine was given 
in anterior myocardial infarctions only at two different doses 
and again it was shown that at a dose of 70 µg/kg min for 
3 hours and in parallel with thrombolysis, it reduced the 
infarct size especially if the thrombolysis started within the 
ﬁ  rst 3 hours (Ross et al 2005). Acadesine, which is an agent 
that facilitates the effect of adenosine, was used in patients 
who underwent CABG. Patients treated with acadesine 
had fewer postoperative myocardial infarctions and better 
clinical outcome (Mangano et al 2006). Nicorandil, which 
opens the mitochondrial KATP channels, has been used in two 
multicenter clinical trials, CEASAR-2 and IONA, with very 
promising results (Patel et al 1999; the IONA study group 
2002). These clinical results suggest that the cardioprotec-
tive effects of preconditioning, well described in animal 
studies, do appear to translate to clinical setting. However, 
direct translation of experimental observations to therapeutic 
intervention is hampered by factors encountered in clinical 
practice such as the necessity of proper time of interven-
tion, the proper duration of the treatment and of course the 
appropriate dosage of drugs.
Apoptosis in the heart
While ischemic injury has long been considered to result in 
necrotic tissue damage, studies over the past 15 years have 
focused attention on apoptosis as a signiﬁ  cant component 
of cell loss during reperfusion injury following myocardial Vascular Health and Risk Management 2006:2(4) 465–475
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infarction (Gottlieb et al 1994; Fliss and Gattinger 1996; 
Gottlieb and Engler 1999; Elsasser et al 2001). Myocardial 
apoptosis has also been documented in response to a variety 
of other cardiac stresses including pressure or volume over-
load, heart failure, diabetic cardiomyopathy, atherosclerosis 
and anti-cancer agents (Haunstetter and Izumo 1998; Feuer-
stein and Young 2000; Valen 2003; Singal et al 2000).
Cardiomyocytes undergoing necrosis and apoptosis show 
characteristic but morphologically and biologically distinct 
features. Necrosis, also called oncosis in the setting of isch-
emia/reperfusion, is an uncontrolled, irreversible process 
characterized by severe cell swelling, ATP depletion, dena-
turation and coagulation of cytoplasmic proteins, breakdown 
of cell organelles and disruption of cell membrane (Searle 
et al 1982; Majno and Joris 1995). It is a destructive process 
as release of cellular content into the surrounding environ-
ment provokes inﬂ  ammation and can cause further damage or 
death to neighboring cells. In contrast, apoptosis is a geneti-
cally controlled, highly regulated process whereby the cell 
commits suicide without inducing inﬂ  ammatory response. 
Apoptosis usually requires energy and it is characterized by 
cell shrinkage, chromatin condensation, DNA fragmenta-
tion, membrane blebbing and formation of apoptotic bodies 
(Majno and Joris 1995; Saraste and Pulkki 2000; Buja 2005). 
The hallmark of apoptosis in intact cells is endonucleolytic 
digestion of nuclear DNA into oligonucleosome-sized frag-
ments (200 bp), in contrast to nonspeciﬁ  c degradation of 
DNA into pieces of random size after loss of membrane 
integrity.
The regulated disassembling of cellular contents, which 
is a feature of apoptosis, is largely conducted by a family of 
cysteine dependent aspartate-directed proteases, the caspases 
(Wang and Lenardo 2000). Fourteen members of this family 
have been identiﬁ  ed in mammals. Caspases-2, -9, -8, and 
-10 are considered apoptosis initiators, and serve to cleave 
and activate apoptosis effectors (caspases-3, -6, and -7). All 
caspases are synthesized as zymogens that contain a prodo-
main, a large subunit and a small subunit, and activation of 
these enzymes is by proteolytic cleavage. Once activated, 
initiator caspases cleave and activate effector caspases and 
a proteolytic cascade is initiated.
There are two principal pathways that lead to caspase 
activation: the extrinsic and intrinsic cell death pathways 
(Danial and Korshmeyer 2004). The extrinsic pathway 
requires the activation of cell surface death receptors (DRs) 
by speciﬁ  c ligands, and allows the cell to respond directly 
to the immediate environment (Figure 2). The vast majority 
of death receptors belong to the tumor necrosis factor recep-
tor (TNFR) superfamily, which includes Fas, TNFR1, and 
DR3–DR6. The binding of death ligands, such as Fas ligand 
or TNF-α, to their cognate receptors at the plasma membrane 
causes homotrimerization of the receptor and recruitment 
of speciﬁ  c adaptor proteins, such as Fas-associated death 
domain and procaspase-8, into a death-inducing signaling 
complex (DISC). This, in turn, leads to activation of initiator 
caspase-8, which subsequently activates effector caspases 3, 
6, and 7 (Hirata et al 1998; Danial and Korshmeyer 2004). In 
contrast, in the intrinsic pathway (Figure 3), the mitochondria 
detect and respond to unfavorable changes in the internal 
environment and play a central role in the integration and 
execution of a wide variety of apoptotic signals. The mito-
chondria provide the energy required for execution of the 
apoptotic program and release of pro-apoptotic proteins such 
as cytochrome c, endonuclease G, and apoptosis-inducing 
factor. Release of these substances occurs during opening 
of the mitochondrial permeability transition (MPT) pore, a 
Death Receptors: Fas, TNFR1, DR 3-6
Ligands: Fas ligand
TNFa
TRAIL
Pro caspase 8
Active caspase 8
Caspases 3,6,7
Figure 2 Schematic representation of the death receptor (extrinsic) pathway of caspase activation to provoke the mechanism of apoptosis.Vascular Health and Risk Management 2006:2(4) 465–475
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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large non-selective ion channel in the outer mitochondrial 
membrane. Gating of the MPT pore is controlled by a com-
bination of calcium, redox potential, pH and transmembrane 
voltage; when the MPT is opened, the normally impervious 
mitochondrial membrane undergoes a reversible transition 
to permeability (Zoratti and Szab’o 1995; Chelli et al 2001). 
Either brief or sustained MPT opening can lead to apoptosis 
(Bishopric et al 2001). On release from mitochondria, cyto-
chrome c forms a complex with procaspase-9 and a cytosolic 
cofactor, Apaf-1 (Li et al 1997; Zou et al 1999). In the pres-
ence of sufﬁ  cient ATP, caspase-9 undergoes autocatalytic 
cleavage to create an active ‘apoptosome’ that cleaves cas-
pase-3 and initiates the apoptotic program. Thus, the extrinsic 
and intrinsic pathways have different initiator caspases but 
converge at the level of the effector caspases.
The intrinsic pathway of apoptosis is regulated by 
members of the Bcl-2 family. This family is composed of 
anti-apoptotic eg, Bcl2, Bcl-xL, Bcl-w, A1, and Mcl-1 and 
pro-apoptotic proteins eg, Bax, Bad, Bak, Bid, Bim, Bnip3, 
Bnip3L (Nix), and Bik. All of these proteins possess up 
to four conserved regions known as Bcl-homology (BH) 
domains (Cory et al 2003). The principal site of action of the 
Bcl-2 family proteins is at the mitochondria, where they regu-
late cytochrome c release and caspase activation. The exact 
mechanisms by which Bcl-2 proteins modulate apoptosis are 
still subject to much debate and controversy. One hypothesis 
is that both pro-apoptotic and anti-apoptotic Bcl-2 proteins 
bind directly to components of the mitochondrial pore, 
leading to either its opening or closure, respectively (Gross 
et al 1999; Mattson and Kroemer 2003). A second hypothesis 
is that upon activation, pro-apoptotic members such as Bax 
and Bak are inserted into the outer mitochondrial membrane 
where they oligomerize to form a protein-permeant pore of 
their own (Mattson and Kroemer 2003).
The most clinical relevant stimulants, which initiate the 
process of apoptosis apart from ischemia/reperfusion, include 
pressure or volume overload, cellular calcium overload, oxy-
gen derived free radicals, increased levels of catecholamines 
and angiotensin II, Fas ligand, TNF-α, as well as decreased 
coronary ﬂ  ow reserve (Khoynezhad et al 2004; Scarabelli 
et al 2006). It is obvious that there is a complex interrelation 
between all the above factors. Decreased coronary ﬂ  ow 
reserve, for example, results in periods of ischemia and 
reperfusion and in generation of oxygen-derived free radi-
cals. Angiotensin II may cause pressure overload and heart 
failure results in increased circulating catecholamine levels. 
All the above mentioned conditions may lead to contractile 
dysfunction of the heart, to dysrhythmias and to cell death 
because of apoptosis or necrosis. The rationale of current 
therapy is mainly to modify myocyte dysfunction and to 
minimize the intensity of the lethal injury acting on the heart. 
Well documented clinical interventions such as restoration of 
ischemia by pharmacological or interventional means, valve 
replacement or surgical correction of any anatomic abnor-
malities which may be considered responsible for pressure 
or volume overload, use of beta blockers, ACE inhibitors or 
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Figure 3 Schematic representation of the mitochondrial death (intrinsic) pathway leading to the formation of apoptosome, activation of caspases and apoptosis.Vascular Health and Risk Management 2006:2(4) 465–475
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The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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angiotensin II receptor antagonists may prevent, suppress or 
restore cardiac dysfunction. However, preservation of cells 
subjected to lethal injury remains an attractive goal and inhi-
bition of cardiac myocyte apoptosis may represent a novel 
approach for treatment of cardiac disease. For this reason, a 
better understanding of the pathways of apoptosis and their 
regulation is required. Therapeutic approaches such as the 
use of inhibitors of TNF-α, caspases and sodium-hydrogen 
exchanger, upregulation of insulin like growth factor-1, anti-
oxidants, ischemic preconditioning, which will be discussed 
in the next section, and others are currently under investiga-
tion (Gill et al 2002; Khoynezhad et al 2004).
Preconditioning and apoptosis
Accumulating evidence from in vivo and in vitro studies 
suggests that ischemic preconditioning signiﬁ  cantly reduces 
DNA fragmentation (Figure 4) and apoptotic myocyte death 
that is associated with ischemia/reperfusion in isolated rab-
bit and rat heart (Gottlieb et al 1996; Maulik et al 1999; 
Nakamura et al 2000; Zhao and Vinten-Johansen 2002; 
Lazou et al 2006). In addition, activation of receptors that are 
involved in the initiation of the mechanism of precondition-
ing, such as δ-opioid and bradykinin, also results in reduced 
apoptosis after ischemia/reperfusion (Okubo et al 2004; Feng 
et al 2005). It is clear from these studies that attenuation of 
apoptosis by ischemic preconditioning is associated with 
a reduction in infarct size analysed early at reperfusion. It 
is not known, however, whether a reduction in infarct size 
measured days after reperfusion is achieved by inhibiting 
apoptosis since apoptosis progresses after reperfusion over 
a number of days. The potential mechanisms underlying 
preconditioning attenuated myocardial apoptosis have not 
been fully clariﬁ  ed and they are under intense investigation. 
However, a number of mediators have been implicated.
Several studies have shown that preconditioning inhibits 
apoptosis by reducing the burst of reactive oxygen species gen-
erated from inﬂ  ammatory cells (ie, PMNs and macrophages) 
and noninﬂ  ammatory cell types (ie, endothelial cells and 
myocytes). In this regard, antioxidants and free radical scaven-
gers have been reported to inhibit the appearance of apoptosis 
(Karzelewski et al 1999; Zhao and Vinten-Johansen 2002). 
Other studies have implicated that preconditioning reduces 
myocardial apoptosis through altering the balance between 
anti-apoptotic and pro-apoptotic proteins, the release of 
cytochrome c from mitochondria, caspase activation, and 
activation of protein kinase C isozymes. Preconditioning 
causes a decrease in pro-apoptotic Bax and increase in the 
anti-apoptotic Bcl-2 proteins resulting in an altered Bcl-2/Bax 
ratio and attenuation of cytochrome c release from mito-
chondria (Maulik et al 1999, 2000; Nakamura et al 2000). 
Inhibition of caspase activity, a key event in the development 
of apoptosis, has also been demonstrated in preconditioning 
(Piot et al 1999). A reduction in ceramide production during 
sustained ischemia has been suggested to reduce apoptosis 
in rabbit hearts (Argaud et al 2004). However, an interrela-
tionship between changes in the expression of Bcl-2 family 
proteins, mitochondrial activity and reduction of apoptosis 
after ischemia/reperfusion by ischemic preconditioning needs 
to be further investigated in in vivo models.
As discussed above, PKC has a central role in ischemic 
preconditioning. In particular, activation of PKCε is impor-
tant in the preservation of cell viability. Although the effect 
of ischemic preconditioning on necrosis through activation 
of PKC isoforms has been intensively investigated (Yellon 
and Downey 2003), only a few studies have shown that 
preconditioning reduces apoptosis by a PKC-dependent 
pathway. Okamura et al (1999) showed that blockade of PKC 
may interrupt the protective effect of preconditioning and 
simultaneously it may promote the mechanism of apoptosis. 
Furthermore, PKCε but not PKCδ is involved in the inhibition 
of apoptosis by preconditioning after simulated ischemia and 
reoxygenation (Liu et al 2001).
The mitochondrial KATP channels signiﬁ  cantly contribute 
to the mechanism of protection in ischemic precondition-
ing by the generation of the oxygen-derived free radicals. 
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Figure 4 Effect of ischemic preconditioning on DNA fragmentation in rabbit 
hearts subjected to ischemia/reperfusion Lane 1 represents control non-ischemic 
tissue; lane 2 represents ischemic tissue after ischemia without reperfusion; lanes 
3 and 4 represent ischemic tissue after ischemia/reperfusion in nonpreconditioned 
and preconditioned hearts, respectively. M, marker lane (from Lazou et al 2006).Vascular Health and Risk Management 2006:2(4) 465–475
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The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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Opening of these channels by pharmacological means like 
nicorandil or diazoxide, trigger the mechanism of protection 
while the addition of 5HD blunts this effect (Pain et al 2000; 
Sato et al 2000; Iliodromitis et al 2003; O’Rourke 2004). 
It is of interest that diazoxide is also capable in preventing 
apoptosis and again the simultaneous use of 5HD abolishes 
this beneﬁ  t (Ardehali et al 2005). In addition to direct effects 
on mitochondrial function, opening of mitochondrial KATP 
channels may have secondary effects on cell signaling such 
as activation of PKCε (Liu et al 2002).
As mentioned above, activation of kinases of the RISC 
pathway has been implicated in mediating the cardioprotec-
tion associated with ischemic preconditioning (Housenloy 
et al 2005; Hausenloy and Yellon 2007). Recent studies 
have shown that pharmacological activation of these kinases 
is associated with recruitment of anti-apoptotic signaling 
components such as the phosphorylation and inhibition of the 
proapoptotic proteins Bax and Bad, the inhibition of caspase 
3 activation, the phosphorylation and activation of p70S6K 
(which acts to inhibit Bad) and the phosphorylation and 
activation of the antiapoptotic protein Bcl-2 (Harada et al 
2001; Hausenloy and Yellon 2007). In addition, the inhibition 
of the mitochondrial permeability transition pore (MTP), a 
mitochondrial channel which mediates cell death at the time 
of myocardial reperfusion by uncoupling oxidative phos-
phorylation and inducing mitochondrial swelling (Hausenloy 
and Yellon 2003), has been identiﬁ  ed as a downstream target 
of the RISK pathway (Davidson et al 2006; Bopassa et al 
2006). Although it has been shown that ischemic precondi-
tioning prevents the increased permeability of the transition
pore by the activation of kinases, Akt, PI3 kinase, and 
ERK1/2, the mechanism through which the RISK pathway 
inhibits the opening of the MTP is unclear.
In conclusion, ischemic preconditioning is a protective 
mechanism in limiting the infarct size and there is a great 
body of evidence that it reduces both necrosis and apoptosis. 
We expect that in the future the acquired experience and the 
increased knowledge of the underlying mechanisms in pre-
conditioning and apoptosis would allow a more appropriate 
use of the proper pharmacological agents that would mimic 
preconditioning and that confer reduction of both necrosis 
and apoptosis. However, the translation of the laboratory 
ﬁ  ndings in the clinical practice should be performed very 
cautiously and with prudence.
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Abstract: Despite numerous studies on women’s cardiac health throughout the past decade, the
number of female deaths caused by cardiovascular disease still rises and remains the leading cause
of death in women in most areas of the world. Novel studies have demonstrated that cardiovascular
disease, and more specifically coronary artery disease presentations in women, are different than
those in men. In addition, pathology and pathophysiology of the disease present significant
gender differences, which leads to difficulties concerning diagnosis, treatment and outcome of the
female population. The reason for this disparity is all steps for female cardiovascular disease
evaluation, treatment and prevention are not well elucidated; and an area for future research. This
review brings together the most recent studies published in the field of coronary artery disease
in women and points out new directions for future investigation on some of the important issues.
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Introduction
The first female-specific recommendations for preventive cardiology were published in
1999 (Mosca et al 1999). Even though research in the treatment of cardiovascular disease
(CVD) had advanced in many areas, it remains the leading cause of death in women in
most parts of the world. Studies have shown that 500 thousand women die of CVD every
year in the United States, somewhat near one death every minute (American Heart
Association 2003). Such index exceeds not only the number of deaths in men, but also the
next seven causes of death in women combined, and more importantly, coronary artery
disease (CAD) is believed to be the major cause responsible for these deaths (American
Heart Association 2003). Over a quarter of a million deaths per year are attributed to CAD
alone in the United States (Merz et al 2004). Although already high, these figures are
expected to rise even more during the next decades, due to an increase of diabetes and
obesity, as well as the aging of the world population (Merz et al 2004).
Even though women have a higher frequency of chest pain/angina than men, the
incidence of obstructive CAD in the female population is lower when compared with
men with similar symptoms (Kenedy et al 1982; Diamond et al 1983; Merz et al 1999). In
addition, it would appear that young women with obstructive CAD have a worse
prognosis after acute myocardial infarction (AMI), whereas older women in similar
circumstances often present with larger number of comorbidities that adversely influence
the outcome, when compared to men (Coronado et al 1997). Women with acute coronary
syndromes (ACS) are also less likely to receive rapid effective diagnosis and treatment
than are men (Ayanian and Epstein 1991; Maynard et al 1996; Pope
et al 2000).
Regarding the North American population, the Women’s Ischemic Syndrome
Evaluation (WISE) study workshop (Hayes et al 2004; Maseri 2004; Nabel et al 2004;
Pepine et al 2004; Shaw et al 2004; Waters et al 2004) from the National Heart, Lung and
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